Hematology · PANCE / PANRE

Sickle Cell Disease

Autosomal recessive hemoglobinopathy (HbSS) causing chronic hemolytic anemia and vaso-occlusive crises.

Also known as: SCD, HbSS, sickle cell anemia, sickle cell disease

Overview

Group of inherited hemoglobinopathies caused by a point mutation in the beta-globin gene (Glu→Val at position 6). Homozygous HbSS produces sickle cell anemia; HbSC and HbS/beta-thalassemia are clinically related compound heterozygous states. Sickle cell trait (HbAS) is generally asymptomatic.

Epidemiology

Most common hemoglobinopathy in the US; ~100,000 affected, predominantly Black/African ancestry (~1 in 365 Black births). HbS trait carriers ~8% of US Black population. Geographic distribution overlaps with historical malaria endemicity (heterozygote advantage).

🔒 Free preview limit reached

Keep reading — start your free trial

You've read your 2 free diagnosis previews. Create your free account to unlock the full Sickle Cell Disease outline — plus all 514 diagnoses, 3,500+ board-style questions, flashcards, and an AI tutor. Your 7-day free trial includes everything, and there's no credit card required.

Free to start · No credit card · Cancel anytime

Risk factors

  • Autosomal recessive: both parents must carry HbS, HbC, or beta-thalassemia variant
  • African, Mediterranean, Middle Eastern, Indian, and Caribbean ancestry
  • Triggers for vaso-occlusion: hypoxia, dehydration, infection, acidosis, cold exposure, stress, high altitude

Pathophysiology

HbS polymerizes when deoxygenated, deforming red cells into a sickle shape. Sickled cells are rigid, adhesive to endothelium, and short-lived (lifespan 10-20 days vs normal 120). Two consequences: chronic hemolytic anemia and microvascular occlusion → ischemia/infarction of multiple organs. Repeated splenic infarction → functional asplenia by early childhood, increasing risk of encapsulated organism infections.

Clinical presentation

Symptoms

  • Vaso-occlusive pain crises — deep bony pain in back, chest, extremities; lasts hours to days
  • Fatigue, dyspnea from chronic anemia (baseline Hb 6-9 g/dL)
  • Dactylitis (hand-foot syndrome) — first manifestation in infants 6-12 months
  • Recurrent infections (encapsulated organisms: pneumococcus, H. flu, meningococcus, Salmonella)
  • Priapism, leg ulcers, delayed growth and puberty
  • Stroke symptoms (children), pulmonary hypertension (adults)

Signs / physical exam

  • Pallor with scleral icterus (chronic hemolysis)
  • Splenomegaly in young children, autosplenectomy by ~5 years
  • Bone tenderness over affected areas during crisis
  • Retinopathy on fundoscopy (especially HbSC)
  • Cardiomegaly, systolic flow murmur

Classic findings

African-American child with dactylitis at 6-12 months age and family history of sickle cell disease.

Differential diagnosis

  • Acute chest syndrome — New pulmonary infiltrate + fever/respiratory symptoms in SCD patient — leading cause of death; treat with antibiotics, transfusion, bronchodilators, analgesia
  • Vaso-occlusive crisis — Severe deep bony pain without infiltrate or other organ failure; treat with hydration, analgesia, oxygen if hypoxic
  • Splenic sequestration — Pediatric SCD, acute splenomegaly, drop in Hb >2 g/dL, hypovolemia; medical emergency, transfuse
  • Aplastic crisis — Sudden severe anemia with low reticulocytes, often parvovirus B19; transfusion supportive
  • Hemolytic crisis — Increased baseline hemolysis (G6PD coincident, drug-induced, hyperhemolysis from transfusion)
  • Osteomyelitis — Salmonella is classic in SCD; clinically overlaps with bone infarction; MRI and blood cultures discriminate
  • Stroke — Up to 11% of children with SCD by age 20; TCD screening identifies high-risk; treat with exchange transfusion

Diagnostic workup

Diagnostic criteria

Hemoglobin electrophoresis showing HbSS, HbSC, or HbS/beta-thalassemia pattern, typically identified on newborn screen.

Labs

  • Universal newborn screening with hemoglobin electrophoresis (or HPLC) in all US states
  • Hemoglobin electrophoresis: HbSS shows ~90% HbS, no HbA, elevated HbF; HbSC shows HbS + HbC, no HbA
  • CBC — chronic normocytic anemia (Hb 6-9), reticulocytosis, leukocytosis at baseline
  • Peripheral smear — sickle cells, target cells, Howell-Jolly bodies (asplenia), nucleated RBCs
  • LDH elevated, haptoglobin low, indirect bilirubin elevated (chronic intravascular and extravascular hemolysis)
  • Sickle solubility test (Sickledex) — screening only, does not differentiate trait from disease

Imaging

  • CXR if respiratory symptoms — exclude acute chest syndrome (new infiltrate)
  • Transcranial Doppler annually ages 2-16 — TCD velocity >200 cm/s indicates high stroke risk
  • MRI brain for stroke evaluation; MRI of bone if osteomyelitis vs infarction unclear
  • Echocardiogram for pulmonary hypertension screening in adults

Diagnostic algorithm

flowchart TD
  A[HbSS homozygote] --> B[HbS polymerization<br/>when deoxygenated]
  B --> C[RBC sickling<br/>rigid, adhesive]
  C --> D[Chronic hemolysis<br/>Hb 6-9, retic ↑, LDH ↑]
  C --> E[Microvascular<br/>occlusion]
  E --> F[Vaso-occlusive<br/>pain crisis]
  E --> G[Acute chest<br/>syndrome]
  E --> H[Stroke]
  E --> I[Splenic infarction<br/>→ autosplenectomy]
  E --> J[Avascular necrosis]
  I --> K[Encapsulated<br/>organism infection<br/>S. pneumoniae, H. flu,<br/>Salmonella]
  D --> L[Pigment gallstones]
  D --> M[Pulmonary HTN]
Sickle cell disease pathophysiology — single point mutation drives both hemolytic and vaso-occlusive complications.

Treatment

First-line

  • Hydroxyurea — disease-modifying therapy; increases HbF and reduces sickling; indicated for all SCD patients ≥9 months; reduces vaso-occlusive crises, acute chest syndrome, transfusion need, and mortality
  • Penicillin prophylaxis (penicillin V 125 mg BID <3 years, 250 mg BID ages 3-5; continue to age 5 minimum) — reduces pneumococcal sepsis
  • Routine immunizations PLUS pneumococcal (PCV13/PCV15 + PPSV23), meningococcal (MenACWY + MenB), and annual influenza
  • Folic acid 1 mg daily (chronic hemolysis)
  • Vaso-occlusive crisis management: aggressive hydration, opioid analgesia (morphine, hydromorphone — avoid meperidine), oxygen if hypoxic, treat underlying trigger
  • Acute chest syndrome: broad-spectrum antibiotics (ceftriaxone + azithromycin), incentive spirometry, simple or exchange transfusion based on severity
  • Exchange transfusion for acute stroke, severe ACS, multiorgan failure, priapism unresponsive to conservative measures

Second-line / adjunct

  • L-glutamine — reduces frequency of vaso-occlusive crises
  • Crizanlizumab (P-selectin inhibitor) — monthly IV, reduces vaso-occlusive crisis frequency
  • Voxelotor — increases hemoglobin oxygen affinity, raises Hb; withdrawn from market in 2024 due to mortality signal
  • Chronic transfusion for stroke prevention (TCD >200) or recurrent ACS — requires iron chelation (deferasirox, deferiprone, deferoxamine)
  • Allogeneic hematopoietic stem cell transplant — only curative option historically; matched sibling donor preferred
  • Gene therapy — exa-cel (CRISPR/Cas9 editing of BCL11A) and lovo-cel (lentiviral beta-globin gene addition) FDA approved 2023 for severe SCD

Complications

  • Acute chest syndrome — leading cause of mortality in adults
  • Stroke — peak ages 2-9 in children; recurrent without secondary prevention
  • Pulmonary hypertension, chronic kidney disease, hyposthenuria
  • Avascular necrosis of femoral/humeral head
  • Retinopathy (especially HbSC), leg ulcers, priapism, cholelithiasis (pigment stones)
  • Functional asplenia — pneumococcal sepsis is the historic leading cause of pediatric mortality
  • Iron overload from chronic transfusion
  • Alloimmunization, delayed hemolytic transfusion reaction, hyperhemolysis syndrome

PANCE pearls

  • Hydroxyurea works primarily by inducing HbF (fetal hemoglobin), which does not sickle; benefits accrue over weeks to months. Monitor CBC for myelosuppression.
  • Salmonella osteomyelitis is the classic SCD-associated infection; Staphylococcus aureus is still the most common organism overall.
  • Parvovirus B19 causes transient aplastic crisis — severe anemia with reticulocyte count <1%.
  • Howell-Jolly bodies on smear indicate functional asplenia and the need for encapsulated-organism prophylaxis.
  • Avoid meperidine — accumulation of normeperidine causes seizures, especially with renal dysfunction.
  • Exchange transfusion (not simple) is preferred when HbS reduction is needed quickly without volume overload — acute stroke, severe ACS.
  • TCD screening starting at age 2 has dramatically reduced primary stroke incidence in SCD children (STOP trial).

References

  • ASH 2020 — American Society of Hematology 2020 guidelines for sickle cell disease: management of acute and chronic complications
  • NHLBI 2014 — Evidence-Based Management of Sickle Cell Disease: Expert Panel Report (NHLBI 2014)
  • STOP Trial — Prevention of a First Stroke by Transfusions in Children with Sickle Cell Anemia (Adams et al., NEJM 1998)
  • MSH Trial — Effect of Hydroxyurea on the Frequency of Painful Crises in Sickle Cell Anemia (Charache et al., NEJM 1995)
  • Frangoul et al. — Exagamglogene autotemcel for Severe Sickle Cell Disease (NEJM 2024)

Practice Hematology questions on FirstPassPA

Turn this outline into retention. 3,500+ board-style questions with an AI tutor that explains every answer — free to start, no card required.

Start studying free → Browse all 514 diagnoses

Educational use only. This outline is a study aid for PA students and is not medical advice or a substitute for clinical judgment. FirstPassPA is an independent study tool and is not affiliated with, endorsed by, or sponsored by NCCPA. PANCE® and PANRE® are registered trademarks of the National Commission on Certification of Physician Assistants.